Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891665 | 0.89 | KDM4E (0.44) | KDRNR4A1SCN9APRKCIKDM4E | |
| SCHEMBL13211123 | 0.89 | KDM4E (0.44) | KDRNR4A1SCN9APRKCIKDM4E | |
| SCHEMBL2891666 | 0.89 | KDM4E (0.44) | KDRNR4A1SCN9APRKCIKDM4E | |
| SCHEMBL2894893 | 0.88 | KDR (0.38) | KDREGFR | |
| SCHEMBL13211132 | 0.88 | KDR (0.38) | KDREGFR | |
| SCHEMBL13838688 | 0.80 | HCAR3 (0.40) | — | |
| SCHEMBL12329516 | 0.79 | NOS3 (0.50) | NR4A1SCN9APRKCIKDM4EMAPK14 | |
| SCHEMBL1435338 | 0.75 | ALOX5AP (0.42) | KDRNR4A1SCN9APRKCI | |
| SCHEMBL2890910 | 0.74 | P2RX3 (0.38) | KDRNR4A1SCN9APRKCIEGFR | |
| SCHEMBL5764943 | 0.73 | RAF1 (0.47) | KDRPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | KDR 1078/4885NR4A1 3218/4885SCN9A 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.